Quarterly Activity Report for 31 December 2020 — Appendix 4C

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on Company activities for the quarter ending 31 December 2020 (Q4 FY2020).

Q4 Highlights:

  • Raised $5.6 million (net of costs) in oversubscribed placement, with funds to be used on product development and manufacturing scale-up
  • MagSenseTM HER2 breast cancer Phase I study open for enrolment, with Monash Health established as first clinical site

Read the Quarterly Activity Report for December 31, 2020.